Parametric modelling of cost data: some simulation evidence by Briggs, A.H. et al.
 
 
 
 
 
 
Briggs, A. and Nixon, R. and Dixon, S. and Thompson, S. (2005) 
Parametric modelling of cost data: some simulation evidence. Health 
Economics 14(4):pp. 421-428. 
 
 
 
 
 
 
 
http://eprints.gla.ac.uk/4151/ 
 
Deposited on: 9 May 2008 
 
 
Glasgow ePrints Service 
http://eprints.gla.ac.uk 
Parametric modelling of cost data: some simulation evidence
Andrew Briggsa,*, Richard Nixonb, Simon Dixonc and Simon Thompsonb
aUniversity of Oxford, UK
bMRC Biostatistics Unit, Cambridge, UK
cUniversity of Sheﬃeld, UK
Summary
Recently, commentators have suggested that the distributional form of cost data should be explicitly modelled to
gain eﬃciency in estimating the population mean. We perform a series of simulation experiments to evaluate the
usual sample mean and the mean estimator of a lognormal distribution, in the context of both theoretical
distributions and three large empirical datasets. The sample mean is always unbiased, but is somewhat less eﬃcient
when the population distribution is truly lognormal. However the lognormal estimator can perform appallingly
when the true distribution is not lognormal. In practical situations, where the true distribution is unknown, the
sample mean generally remains the estimator of choice, especially when limited sample size prohibits detailed
modelling of the cost data distribution. Copyright
Introduction
The appropriate analysis of cost data generated by
clinical trials is problematic. While the usual
outcome of interest is the population mean cost
for a particular treatment, the distribution of cost
data is generally highly skew because a few
patients incur very large costs.
A number of commentators have made recom-
mendations for the analysis of cost data. Briggs
and Gray [1] have argued against the use of
standard non-parametric methods for analysing
cost data, precisely because of the necessary focus
on mean cost. While they considered that there
may be some merit in transforming cost data, they
emphasised the importance of presenting cost
estimates on the untransformed scale.
Thompson and Barber [2] however argued
strongly that transformation of cost data is not
appropriate. They recommended the use of the
sample mean as an estimator, with conﬁdence
limits derived either from standard asymptotic
theory, or from non-parametric bootstrapping of
the sample mean.
In a recent contribution, O’Hagan and Stevens
have criticised the unequivocal nature of Thomp-
son and Barber’s recommendations [3]. They argue
that while the appropriate focus of cost analysis is
clearly the population mean cost, where cost data
are not normally distributed the sample mean is
not necessarily the most eﬃcient estimator. They
argue that, if cost data truly follow a lognormal
distribution, there will be eﬃciency gains from
using exp(lm+lv/2) as an estimator of the mean
cost in the population, where lm and lv are the log
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scale sample mean and variance, respectively.
While O’Hagan and Stevens used an example of
apparently lognormally distributed costs, they are
careful not to argue for making a lognormal
assumption in general. Rather they argue that cost
data should be appropriately modelled, leaving
something of a question as to what that appro-
priate distribution might be.
Other commentators have been less circumspect.
In particular, Zhou, in a series of articles [4–7], has
focused attention on the use of estimators based
on assuming that costs follow a lognormal
distribution. From the reported applied examples,
this assumption is linked to the failure to reject a
null hypothesis of normality on the log scale [8],
with no consideration of whether there are more
appropriate distributions for cost data.
Although the issues related to estimating mean
costs for health care interventions have recently
come to the fore for health economists conducting
economic evaluations alongside clinical trials,
these issues are by no means new. Similar issues
in the risk-adjustment literature were raised in
relation to estimating costs in the RAND insur-
ance experiment in the early 1980s [9,10], where
log transformation was found to yield better
compliance with modelling assumptions, but
where prediction on the untransformed scale was
the ultimate goal. This requirement led Duan to
propose the ‘smearing estimator’ that could be
used to correct for the bias that occurs if
expectations on the transformed scale are back
transformed [11]. In developing this initial frame-
work, commentators such as Manning and Mulla-
hy have also focused much attention on the use of
transformation as a method for improving the
estimation of mean cost relating to health care
costs and expenditures [12–15].
The purpose of this paper is to evaluate
two alternative estimators of population mean
cost. First, we look at their relative performance
under a number of assumed parametric distribu-
tions for cost. Second, we repeat the comparison in
an empirical context using three datasets where
large numbers of individual level costs are avail-
able. The aim is to highlight not only the potential
eﬃciency gains to be obtained from choosing the
appropriate estimator, but also any potential
problems of choosing the incorrect estimator.
We return to the link between the estimation
of costs for cost-eﬀectiveness analysis and the
estimation of costs in the risk-adjustment literature
in the discussion.
Simulating from parametric
distributions
Two parametric distributions were employed to
generate cost data. These were the lognormal and
Gamma distributions, both of which are used in
practice to model positively skewed cost data. The
appropriate (maximum likelihood) estimator of
the population mean of a Gamma distribution is
the sample mean, whereas the appropriate estima-
tor of the population mean of a lognormal
distribution is exp(lm+lv/2), as described above.
Estimation of a conﬁdence interval based on the
sample mean estimator is straightforward using
standard asymptotic assumptions. Obtaining the
conﬁdence interval for the lognormal estimator is
a non-trivial problem since it is a function of two
transformed sample estimates. The method used in
this paper is that outlined in a review paper by
Zhou [8].
For each distribution, the population mean was
set to be 1000 and ﬁve choices of coeﬃcient of
variation (CoV, the ratio of the standard deviation
to the mean = 0.25, 0.5, 1.0, 1.5, 2.0) were used to
deﬁne the parameters of the distribution. The
resulting distributions (Figure 1) are plausible
representations of cost data. These are the
population distributions from which samples are
drawn in the simulation exercise.
Samples of ﬁve diﬀerent sizes (n=20, 50, 200,
500, 2000) were drawn from each distribution and
for each coeﬃcient of variation. This represented a
total of 50 diﬀerent simulation experiments. For
each experiment, with 10 000 replications, the
sample mean and the lognormal estimator were
used to estimate the population mean. For each
simulation, the bias (average estimate minus 1000)
and coverage probability (proportion of 95%
conﬁdence intervals containing 1000) were calcu-
lated. In order to summarise both bias and
precision, the root mean square error (RMSE)
was calculated, which equals the square root of the
mean [estimate 1000]2 in each simulation.
As expected, the RMSE reduces with decreasing
coeﬃcient of variation and increasing sample size,
no matter which combination of underlying
distribution or estimator is chosen (Table 1).
When the data are truly from a lognormal
distribution, both the lognormal estimator and
the sample mean are unbiased, but the lognormal
estimator is more precise – all of the cells of the
lower-right matrix in Table 1 show a smaller
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RMSE than those in the lower-left matrix.
However, the gain in precision is only
moderate; the ratio of RMSEs always remains
greater than 84% in Table 1. By contrast,
when a lognormal estimator is applied to data
that follow a Gamma distribution, the results are
disastrous. Although, for low coeﬃcients of
variation there is little to choose between the
estimators, where the coeﬃcient of variation is
large, the lognormal estimator performs very
poorly. This is because the lognormal estimator
is severely biased in these cases, while the sample
mean remains unbiased.
These results are echoed by the coverage
probabilities of the conﬁdence intervals for the
diﬀerent estimators (Table 2). Increasing coeﬃ-
cients of variation and decreasing sample size
generally lead to poorer coverage (less than 95%).
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Figure 1. Parametric distributions used to represent population cost distributions: upper panel shows ﬁve lognormal distributions
and lower panel shows ﬁve gamma distributions. Parameters of the distributions are set so that the mean cost is 1000 with
coeﬃcients of variation 0.25, 0.5, 1.0, 1.5 and 2.0
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Again the lognormal estimator exhibits improved
performance over the sample mean if the data are
truly lognormal. However, the misapplication of
the lognormal estimator to Gamma distributed
data leads to some very poor coverage results,
again due to bias.
Simulations from observed cost
datasets
Since it is unlikely that population cost distribu-
tions really follow a well-behaved functional form
we repeat the comparison of estimators using three
large datasets of patient-level cost data. These are
treated as population distributions from which
samples are drawn in the simulation. The three
datasets used for empirical simulations are de-
scribed below.
The CPOU data: These data were constructed
for an economic evaluation of a Chest Pain
Observation Unit operating within the A and E
department of a single large teaching hospital [16].
Patients with acute chest pain, undiagnosed by
clinical assessment, electrocardiogram and chest
radiograph, were recruited and followed-up to
6 months. Nine hundred and seventy-two patients
were recruited to the study. Total cost (2001/2002
prices) was constructed from the initial 6 hours of
care, length of stay, parenteral drug therapy,
diagnostic tests, reattendances and readmissions,
outpatient attendances and cardiology procedures.
The IV ﬂuids data: These cost data were
constructed for a randomised controlled trial of
two prehospital intravenous ﬂuids protocols for
paramedics in patients with serious trauma [17].
1309 patients were entered into the study from two
diﬀerent Ambulance Trusts and costs were con-
structed for 1191 patients. Total cost (1997/1998
prices) was calculated for individual patients up to
6 months post-incident, and included ambulance
costs, ﬂuid costs, A and E costs, inpatient costs,
and ambulatory care.
The Paramedics data: These cost data were
constructed from a controlled study comparing
ambulance technicians and paramedics in patients
with serious trauma [18]. 1852 patients were
entered into the study from three diﬀerent
Ambulance Trusts. Total cost (1996/1997 prices)
was calculated for individual patients up to 6
months post-incident, and included ambulance
costs, ambulance treatment costs, hospital costs,
and ambulatory care.
Summary statistics of the per-patient total cost
are presented in Table 3 for each example. All
three datasets exhibit extreme skewness and
kurtosis (compared to the values of 0 and 3
respectively for a normal distribution). Of interest
is the coeﬃcient of variation which shows that the
standard deviation in the data is roughly twice the
mean for all three datasets – this is the upper range
of the coeﬃcient of variation examined in the
Table 1. Estimated root mean squared error by underlying distribution and estimator for diﬀerent sample sizes and
coeﬃcients of variation
RMSE for sample mean estimator RMSE for exp(lm+lv/2) estimator
Simulation sample sizes Simulation sample sizes
Distribution CoV 20 50 200 500 2000 20 50 200 500 2000
Gamma 0.25 56 35 18 11 6 56 35 18 11 6
0.50 112 71 35 22 11 114 73 38 25 16
1.00 221 141 70 44 22 400 304 241 226 218
1.50 333 214 105 67 34 1388 1097 925 896 878
2.00 440 284 141 89 45 2663 1914 1510 1420 1378
Lognormal 0.25 56 36 18 11 6 56 36 18 11 6
0.50 112 71 35 22 11 112 71 35 22 11
1.00 224 141 72 45 23 221 137 69 43 22
1.50 336 214 109 67 34 328 197 99 61 31
2.00 450 288 143 63 45 419 250 122 54 38
RMSE}root mean squared error; lm}log mean; lv}log variance; CoV coeﬃcient of variation.
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previous simulation experiments based on para-
metric distributions. Taking logs of the cost in
each of the datasets appears to make the distribu-
tions more normal (Table 4, Figure 2).
The simulation experiment (again with 10 000
replications) involved drawing values at random
without replacement from the cost datasets in
order to form samples of varying sizes (n=20, 50,
200, 500). On the basis of these samples, the
estimators of the population mean (sample mean,
and exp(lm+lv/2)) and their corresponding con-
ﬁdence limits were calculated.
The RMSE and coverage probabilities (com-
pared to the sample mean in all the data) are
presented in Table 5. As expected, the RMSE
decreases with increasing sample size. The RMSEs
are similar for the two estimators at the lower
sample sizes, but as the Central Limit Theorem
takes eﬀect, the sample mean becomes the more
accurate. This is echoed in the coverage results
where the rapid deterioration in the coverage
probabilities for the lognormal estimator as
sample size increases is striking. This serves to
emphasise that while the Central Limit Theorem
plays an important role in the validity of the
sample mean as an estimator, increasing sample
size is no guarantee of performance for other
estimators based on parametric assumptions if
those assumptions turn out not to hold.
It is commonly considered that the Central
Limit Theorem applies for samples with greater
than 30 observations, whatever the distribution in
the underlying population. However, this rule of
thumb does not apply to non-symmetric distribu-
tions typical of cost data. Cochran’s alternative
guideline of n > 25Z2 for situations where the
‘principal deviation from normality consists of
marked positive skewness’ [19] is based on Z, the
skewness coeﬃcient in the sample. The guideline
was devised such that a 95% conﬁdence interval
Table 2. Estimated 95% conﬁdence interval coverage probabilities by underlying distribution and estimator for
diﬀerent sample sizes and coeﬃcients of variation
Coverage for sample mean estimator Coverage for exp(lm+lv/2) estimator
Simulation sample sizes Simulation sample sizes
Distribution CoV 20 50 200 500 2000 20 50 200 500 2000
Gamma 0.25 0.93 0.94 0.95 0.95 0.95 0.93 0.94 0.96 0.96 0.95
0.50 0.92 0.93 0.95 0.95 0.95 0.94 0.96 0.97 0.95 0.89
1.00 0.90 0.93 0.95 0.95 0.95 0.97 0.97 0.69 0.18 0
1.50 0.87 0.91 0.94 0.95 0.94 0.99 0.92 0.14 0 0
2.00 0.83 0.89 0.93 0.94 0.95 0.99 0.93 0.20 0 0
Lognormal 0.25 0.92 0.93 0.95 0.95 0.95 0.91 0.93 0.95 0.95 0.95
0.50 0.91 0.93 0.94 0.95 0.95 0.91 0.93 0.94 0.95 0.95
1.00 0.87 0.91 0.93 0.94 0.95 0.90 0.93 0.95 0.95 0.95
1.50 0.83 0.88 0.92 0.94 0.94 0.89 0.93 0.94 0.95 0.94
2.00 0.80 0.86 0.91 0.92 0.94 0.88 0.92 0.94 0.95 0.95
lm}log mean; lv}log variance; CoV coeﬃcient of variation.
Table 3. Summary statistics for per patient total cost in
the three example datasets
CPOU IV Fluids Paramedics
n 972 1191 1852
Mean 518 2693 4233
Sd 1145 7083 7961
Skewness 5.3 4.8 7.5
Kurtosis 37 32 88
CoV 2.2 2.6 1.9
CoV coeﬃcient of variation.
Table 4. Summary statistics for the natural log of cost
for the three example datasets
CPOU IV Fluids Paramedics
n 972 1191 1852
Mean 5.37 6.51 7.70
Sd 1.19 1.32 1.09
Skewness 0.59 1.69 0.05
Kurtosis 3.73 4.72 4.76
CoV 0.22 0.20 0.14
CoV coeﬃcient of variation.
For Evaluation Only.
Copyright (c) by Foxit Software Company, 2004 - 2007
Edited by Foxit PDF Editor
will have an error probability no greater than 6%.
For the three example datasets this suggests that a
minimum sample size of approximately 700 is
required for the CPOU data, 560 for the IV ﬂuids
data and 1400 for the paramedics data. The results
presented in Table 5 for the coverage probabilities
in fact indicate the guideline to be rather
conservative, since the sample mean has coverage
close to 95% at sample sizes of 200, 200 and 500,
respectively. Nevertheless, what is clear is that the
n>30 rule of thumb is totally inappropriate for
cost data.
Comments and conclusions
It was George Box that famously quoted ‘All
models are wrong’ [20] and Nester has added, in
his Applied Statistician’s Creed that ‘No data are
normally distributed’ [21]. For cost data it is highly
unlikely that parametric distributions are anything
other than a simple approximation to the true
distribution. The very construction of cost data –
as a weighted sum of diﬀerent resource counts –
emphasises that total cost distributions are really
mixtures of many other types of distribution. Even
with moderately sized samples drawn from known
distributions the form of that distribution can
often not be reliably ascertained from the data
alone.
The simulation experiments performed here
conﬁrm that when the appropriate distributional
form of cost data is known, a degree of eﬃciency
can be gained from using the estimator appro-
priate for that distribution. However, application
of estimators based on incorrect parametric
assumptions can lead to totally misleading con-
clusions.
The focus of the simulation experiment was the
estimation of mean costs as might be generated
alongside a clinical trial. However, in the risk-
adjustment literature, similar issues have arisen
and other commentators have also presented large
scale simulation experiments to address the issue
of what form of model/estimator is appropriate for
the data. For example, Manning and Mullahy [12]
presented a comprehensive simulation experiment
to explore the use of log-transformation versus
generalised linear modelling (GLM) of cost data.
Their general conclusion was that the choice of
modelling technique was an empirical issue and
they provided an algorithm to help analysts choose
the appropriate approach to their data. More
recently Deb and Burgess have conducted similar
experiments but using real-life health expenditure
data and they conclude much more strongly that
GLMs based on Gamma densities are more
appropriate for risk-adjustment models of cost
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Figure 2. Histograms showing the distribution of log cost in
each of the three example cost datasets
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data than transformation of the dependent vari-
able [22].
The link between what might be described as the
risk-adjustment literature, where modelling of cost
data is widespread, and the health economic
evaluation literature is instructive. In general, the
risk-adjustment literature has found that careful
parametric modelling of cost data leads to more
eﬃcient estimators than simply using OLS
(equivalent to the sample mean). However, in the
risk-adjustment literature, there are typically many
more data points (Deb and Burgess [22] estimated
models based on 10,000–500,000 observations). In
the health economic evaluation literature, where
cost observations are generally collected from
patients recruited to randomised controlled trials,
the sample sizes are typically much less. It is within
the context of such studies, where formal model-
ling of cost data is much more challenging, that we
have tried to focus our simulation study. The real
danger, as our simulations show, is the use of
transformation based on parametric assumptions
that cannot be suﬃciently tested. For example,
Zhou, in a review of analysing cost data generated
alongside clinical trials presents a series of
examples where he emphasises the use of the log
transformation [8]. The only justiﬁcation provided
is failure to reject a hypothesis of normality on the
log scale.
In empirical cost analysis for health economic
evaluation, the true form of the cost distribution
remains unknown. Overall, the sample mean
performs well and is unlikely to lead to inap-
propriate inferences. Only when there are suﬃcient
data to permit detailed modelling and choice of a
suitable parametric distributions, is the use of
other estimators of the population mean war-
ranted.
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